APA (7th ed.) Citation

Goldman, J. W., Cummings, A. L., Mendenhall, M. A., Velez, M. A., Babu, S., Johnson, T. T., . . . Slamon, D. J. (2022). Primary analysis from the phase 2 study of continuous talazoparib (TALA) plus intermittent low-dose temozolomide (TMZ) in patients with relapsed or refractory extensive-stage small cell lung cancer (ES-SCLC). Journal of clinical oncology, 40(16_suppl), 8517. https://doi.org/10.1200/JCO.2022.40.16_suppl.8517

Chicago Style (17th ed.) Citation

Goldman, Jonathan W., et al. "Primary Analysis from the Phase 2 Study of Continuous Talazoparib (TALA) Plus Intermittent Low-dose Temozolomide (TMZ) in Patients with Relapsed or Refractory Extensive-stage Small Cell Lung Cancer (ES-SCLC)." Journal of Clinical Oncology 40, no. 16_suppl (2022): 8517. https://doi.org/10.1200/JCO.2022.40.16_suppl.8517.

MLA (9th ed.) Citation

Goldman, Jonathan W., et al. "Primary Analysis from the Phase 2 Study of Continuous Talazoparib (TALA) Plus Intermittent Low-dose Temozolomide (TMZ) in Patients with Relapsed or Refractory Extensive-stage Small Cell Lung Cancer (ES-SCLC)." Journal of Clinical Oncology, vol. 40, no. 16_suppl, 2022, p. 8517, https://doi.org/10.1200/JCO.2022.40.16_suppl.8517.